3 results
The primary objective is to determine the efficacy of pain control with this type of Peripheral Subcutaneous Field Stimulation (PSFS) at three months and 12 months. The secondary objectives determined at both 3 and 12 months are the assessment of…
Main objectivePart A: To evaluate the safety and efficacy of treatment with VX-371, administered with and without 4.2% hypertonic saline (HS) in subjects with primary ciliary dyskinesia (PCD) who are *12 years of age.Part B: To evaluate the safety…
The primary objective for this study is as follows:* To evaluate clinical benefit in terms of PFS, as assessed by an IRF, for GA101 when used incombination with bendamustine compared with bendamustine alone in patients with indolentNHL refractory to…